Table 2.

Overview of the survival characteristics of the study cohort (cases with available follow-up)

	HGSC (n = 110)	LGSC (n = 81)	mSBT (n = 27)	EC (n = 50)	CCC (n = 106)	MBT (N = 63)	MC (N = 27)
Follow-up (duration in months)
Median	38	43	58	64	37	46	10
Mean	43	55	56	65	46	50	34
Max	251	320	189	171	198	162	123
Survival status
NED	26 (23.6%)	37 (45.7%)	17 (63.0%)	47 (94%)	61 (57.5%)	61 (96.8%)	17 (62.9%)
AWD	60 (54.5%)	24 (29.6%)	6 (22.2%)	2 (4%)	19 (17.9%)	0 (0%)	7 (25.9%)
DOD	24 (21.8%)	11 (13.6%)	3 (11.1%)	1 (2%)	13 (12.3%)	0 (0%)	2 (7.5%)
DTC	0 (0%)	1 (1.2%)	0 (0%)	0 (0%)	3 (2.8%)	0 (0%)	0 (0%)
DUC	0 (0%)	7 (8.6%)	1 (3.7%)	0 (0%)	7 (6.6%)	2 (3.2%)	1 (3.7%)
DOC	0 (0%)	1 (1.2%)	0 (0%)	0 (0%)	3 (2.8%)	0 (0%)	0 (0%)

HGSC high grade serous carcinoma, LGSC low grade serous carcinoma, mSBT micropapillary serous borderline tumor, EC endometrioid carcinoma, CCC clear-cell carcinoma, MBT mucinous borderline tumor, MC mucinous carcinoma, NED no evidence of disease, AWD alive with disease, DOD death of diagnosis, DTC death of treatment complications, DUC death of unknown cause, DOC death of other cause